Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IN10018 + docetaxel
- Development stage
- Phase 1
- Lead developer
- InxMed
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
IN10018 + docetaxel is a combination investigational regimen comprising IN10018 (also known as BI 853520 or ifebemtinib), a selective ATP-competitive small molecule inhibitor of focal adhesion kinase (FAK), and docetaxel, a microtubule-stabilizing chemotherapeutic agent. IN10018 inhibits FAK autophosphorylation and interferes with key pathways involved in cancer cell survival, proliferation, migration, and tumor microenvironment modulation, especially impacting the FAK/AKT/mTOR signaling pathway. Docetaxel disrupts microtubule function, leading to mitotic arrest and apoptosis of rapidly dividing cancer cells. The combination is under early clinical investigation for solid tumors, including locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Preclinical and clinical data suggest IN10018 may overcome resistance mechanisms and enhance chemotherapy and immunotherapy efficacy when combined with traditional agents like docetaxel[1][2][4].
- Other names
- ifebemtinib
02
Targets
FAK (Focal adhesion kinase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on IN10018 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IN10018 + docetaxel.